Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651586 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers
A Phase 2 study of Bacterial Keratitis and Acute Bacterial Corneal Ulcers, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 2
- Study locations
NCT00651586 is a Phase 2 study of Bacterial Keratitis and Acute Bacterial Corneal Ulcers that has completed, run by Allergan. The registered enrollment target is 129 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00651586, a Phase 2 study of Bacterial Keratitis and Acute Bacterial Corneal Ulcers, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates the safety and efficacy of gatifloxacin 0.3% ophthalmic solution compared with ciprofloxacin 0.3% ophthalmic solution in patients with acute bacterial corneal ulcers
Conditions Studied
Interventions
- DRUG Gatifloxacin 0.3% ophthalmic solution
- DRUG Ciprofloxacin 0.3% ophthalmic solution
Study Locations (2)
Texas
- - Galveston
Tamil Nadu
- - Madurai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2003-10 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00651586
The ClinicalTrials.gov registry entry for NCT00651586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bacterial Keratitis appearing as the primary indexed condition, and to 2 interventions - of which Gatifloxacin 0.3% ophthalmic solution is the first listed.
NCT00651586 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Tamil Nadu.
Frequently Asked Questions
What is clinical trial NCT00651586 about?
NCT00651586 is a clinical study titled "Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers". This study evaluates the safety and efficacy of gatifloxacin 0.3% ophthalmic solution compared with ciprofloxacin 0.3% ophthalmic solution in patients with acute bacterial corneal ulcers
What is the current status of trial NCT00651586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2003-10. Estimated completion is 2005-04.
What conditions does trial NCT00651586 study?
This clinical trial studies the following conditions: Bacterial Keratitis, Acute Bacterial Corneal Ulcers.
What interventions are being tested in trial NCT00651586?
The interventions under investigation include: Gatifloxacin 0.3% ophthalmic solution (DRUG), Ciprofloxacin 0.3% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00651586?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00651586 being conducted?
This trial has 2 study locations across Texas, Tamil Nadu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Keratitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.